Abstract The invention is concerned with novel heteroaryl fused cyclic amines of formula (I) wherein A, X1 to X3 Y1 to Y3 Z, R1, R2 m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.